Relationship between MGMT gene expression and treatment effectiveness and prognosis in glioma

Li,Qiang; Guo,Jiang; Wang,Weisheng; Wang,Dingkun

doi:10.3892/ol.2017.6123

Relationship between MGMT gene expression and treatment effectiveness and prognosis in glioma

Authors:
- Qiang Li
- Jiang Guo
- Weisheng Wang
- Dingkun Wang
View Affiliations

Affiliations: Department of Neurosurgery, Laiwu City People's Hospital, Laiwu, Shandong 271100, P.R. China, Department of Neurosurgery, Shouguang City People's Hospital, Shouguang, Shandong 262100, P.R. China, Department of Neurology, Liaocheng Third People's Hospital, Liaocheng, Shandong 252000, P.R. China, Department of Neurosurgery, Tongde Hospital of Zhejiang, Hangzhou, Zhejiang 310012, P.R. China
Published online on: May 5, 2017 https://doi.org/10.3892/ol.2017.6123
Pages: 229-233
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of O6-methylguanine DNA methyltransferase (MGMT) in different grade gliomas were analyzed in relation to its therapeutic effect and impact on disease prognosis. In total, 62 patients with glioma, who were admitted by neurosurgery and received surgical treatment and postoperative conventional chemoradiation, were selected for this study. Expression of MGMT was greater with an increase in brain glioma grade. Gender, age, tumor size and Karnofsky performance status (KPS) score did not differ with MGMT expression (P>0.05). Expression of MGMT in normal brain tissue was slightly significantly different than expression of MGMT in glioma tissue (P<0.05). The short‑term efficacy and survival time of the MGMT-negative expression group were better than those of MGMT-positive expression. MGMT was only treated as an index to monitor tumor recurrence or metastasis and a reference to judge the prognosis of patients. The expression level of MGMT in glioma had no relation with age, gender, tumor size, surgical approach and KPS score. For glioma patients with positive expression of MGMT, antineoplastic drugs of alkylating agent class should be avoided.

View Figures

View References

1	Blumenthal DT, Dvir A, Lossos A, Tzuk-Shina T, Lior T, Limon D, Yust-Katz S, Lokiec A, Ram Z, Ross JS, et al: Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. J Neurooncol. 130:211–219. 2016. View Article : Google Scholar : PubMed/NCBI
2	Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO and Cairncross JG: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Changing paradigms - an update on the multidisciplinary management of malignant glioma. Oncologist. 11:165–180. 2006. View Article : Google Scholar : PubMed/NCBI
3	Kaina B, Christmann M, Naumann S and Roos WP: MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst). 6:1079–1099. 2007. View Article : Google Scholar : PubMed/NCBI
4	Hsu CY, Lin SC, Ho HL, Chang-Chien YC, Hsu SP, Yen YS, Chen MH, Guo WY and Ho DM: Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma. Am J Surg Pathol. 37:264–271. 2013. View Article : Google Scholar : PubMed/NCBI
5	Jacinto FV and Esteller M: MGMT hypermethylation: A prognostic foe, a predictive friend. DNA Repair (Amst). 6:1155–1160. 2007. View Article : Google Scholar : PubMed/NCBI
6	Bocangel D, Sengupta S, Mitra S and Bhakat KK: p53-mediated down-regulation of the human DNA repair gene O⁶-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res. 29:3741–3750. 2009.PubMed/NCBI
7	Molnár J, Engi H, Hohmann J, Molnár P, Deli J, Wesolowska O, Michalak K and Wang Q: Reversal of multidrug resitance by natural substances from plants. Curr Top Med Chem. 10:1757–1768. 2010. View Article : Google Scholar : PubMed/NCBI
8	Tugcu B, Postalci LS, Gunaldi O, Tanriverdi O and Akdemir H: Efficacy of clinical prognostic factors on survival in patients with glioblastoma. Turk Neurosurg. 20:117–125. 2010.PubMed/NCBI
9	Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E, et al: Gene expression profiling predicts response to temozolomide in malignant gliomas. Int J Oncol. 36:1367–1377. 2010. View Article : Google Scholar : PubMed/NCBI
10	Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, et al: Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). J Neurooncol. 125:359–367. 2015. View Article : Google Scholar : PubMed/NCBI
11	Suryadevara CM, Verla T, Sanchez-Perez L, Reap EA, Choi BD, Fecci PE and Sampson JH: Immunotherapy for malignant glioma. Surg Neurol Int. 6 Suppl 1:S68–S77. 2015. View Article : Google Scholar : PubMed/NCBI
12	Chen ZP, Malapetsa A, McQuillan A, Marcantonio D, Bello V, Mohr G, Remack J, Brent TP and Panasci LC: Evidence for nucleotide excision repair as a modifying factor of O⁶-methylguanine-DNA methyltransferase-mediated innate chloroethylnitrosourea resistance in human tumor cell lines. Mol Pharmacol. 52:815–820. 1997. View Article : Google Scholar : PubMed/NCBI
13	Stupp R, Hegi ME, Gilbert MR and Chakravarti A: Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol. 25:4127–4136. 2007. View Article : Google Scholar : PubMed/NCBI
14	Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr and Lopes MB: Temozolomide treatment for aggressive pituitary tumors: Correlation of clinical outcome with O⁶-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 95:E280–E290. 2010. View Article : Google Scholar : PubMed/NCBI
15	Nitta M, Muragaki Y, Maruyama T, Ikuta S, Komori T, Maebayashi K, Iseki H, Tamura M, Saito T, Okamoto S, et al: Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection. Neurosurg Focus. 38:E72015. View Article : Google Scholar : PubMed/NCBI
16	Yuan Q, Matsumoto K, Nakabeppu Y and Iwaki T: A comparative immunohistochemistry of O⁶-methylguanine-DNA methyltransferase and p53 in diffusely infiltrating astrocytomas. Neuropathology. 23:203–209. 2003. View Article : Google Scholar : PubMed/NCBI
17	Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 343:1350–1354. 2000. View Article : Google Scholar : PubMed/NCBI
18	Rimel BJ, Huettner P, Powell MA, Mutch DG and Goodfellow PJ: Absence of MGMT promoter methylation in endometrial cancer. Gynecol Oncol. 112:224–228. 2009. View Article : Google Scholar : PubMed/NCBI
19	Lavon I, Zrihan D, Zelikovitch B, Fellig Y, Fuchs D, Soffer D and Siegal T: Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res. 13:1429–1437. 2007. View Article : Google Scholar : PubMed/NCBI
20	Bobola MS, Blank A, Berger MS and Silber JR: O⁶-methylguanine-DNA methyltransferase deficiency in developing brain: Implications for brain tumorigenesis. DNA Repair (Amst). 6:1127–1133. 2007. View Article : Google Scholar : PubMed/NCBI
21	Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, Nowak AK, Hitchins MP and McDonald KL: The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro Oncol. 17:1589–1598. 2015. View Article : Google Scholar : PubMed/NCBI